Consolidation or maintenance therapy significantly improved progression-free survival and overall survival. Zanubrutinib, lenalidomide, temozolomide, and rituximab (RLZT) combined with or without high ...

A time delay of 14 months on average still exists between the onset of clinical manifestations and the initial suspicion of cardiac amyloidosis. Despite advances in noninvasive diagnostic techniques, ...

Insulin-like growth factor-binding protein 4 protects biliary cells from cellular injury induced by bile salts and promotes the proliferation of biliary cells in PBC. Insulin-like growth ...

Prompt discontinuation of the suspected drug is critical for recovery. Drug-induced immune hemolytic anemia (DIIHA) should be investigated in suspected cases of warm autoimmune hemolytic anemia (warm ...

Segmental analysis showed significant correlations between 3D-STE and CMRI strain measurements across most regions. Two advanced echocardiography techniques reliably detect both global and regional ...

Early tacrolimus + prednisolone + nintedanib therapy markedly improved the forced vital capacity decline slope from –20.9% to +11.2% per year in untreated PPF. Initiating combination therapy with ...

The use of statins was also associated with a reduced risk of major adverse liver outcomes in patients with primary biliary cholangitis (PBC). Statins are associated with a reduced risk of hepatic ...

Cognitive dysfunction, or "brain fog," in patients with scleroderma (also known as systemic sclerosis) can have various negative impacts on quality of life. Larry Luxner, senior correspondent for Rare ...

Key outcomes included high ILD prevalence, postmyopathic PPF in 13.5% of the cohort, higher rates of rapidly progressive ILD and transplantation in postmyopathic PPF, greater rituximab use in PPF, and ...

Combining ETAA1 and ATR improved discrimination between patients and controls, achieving an area under the curve of 0.822 with 74% sensitivity and 72% specificity. Because overexpression of the 3 ...

Immunosuppressants are often used to slow disease progression in ILD-associated AAV, but results tend to be inconsistent. Researchers found that more advanced fibrosis, the presence of usual ...

The amyloid accumulation volume decreased significantly from 591.1 before tafamidis treatment to 213.8 following treatment. Tafamidis treatment inhibits the production of new amyloids in patients with ...